

Lorrene A. Buckley PhD, DABT, ATS



Dr. Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. In her current position as a Vice President at Eli Lilly & Company, she is responsible for the design and execution of nonclinical safety assessments and for all nonclinical aspects of global regulatory submissions and interactions for drugs in the development and commercialization phases.

Dr. Buckley obtained her MS at the University of Arizona and PhD at UNC, Chapel Hill. Her diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research (CIIT, RTI), risk assessment in the chemical & agrochemical industry (FMC Corp), and safety assessment of pharmaceuticals (Sphinx, Eli Lilly).

Dr. Buckley has served in leadership positions with the following professional toxicology organizations: American Board of Toxicology (ABT Board, 2004-2007); the Academy of Toxicological Sciences (ATS: Board, 2015-2017 and Presidential chain, 2021-2024); the Society of Toxicology (SOT Council, 2012-2016); and the American College of Toxicology (ACT: Council 2009-2012 and Presidential chain: 2018-2021). Within the Innovation and Quality (IQ) Consortium for Pharmaceutical Development, she has actively contributed to various inter-industry initiatives as a member of the DruSafe Leadership Group.

Dr. Buckley frequently lectures in various educational and professional settings and has authored numerous journal articles and book chapters concerning approaches to pharmaceutical safety assessment and the toxicologic assessment of environmental contaminants. Her coaching and mentorship of early- and late-stage professionals internally at Lilly and externally through professional society connections represents an important contribution to the success and growth of our field. In this regard, Dr. Buckley was awarded ACT's Mildred Christian Award in 2024 and Lilly Research Laboratories President's Award as a "Coach of the Year" in 2025.